Ledyard National Bank Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ledyard National Bank trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,435 shares of the biopharmaceutical company’s stock after selling 198 shares during the quarter. Ledyard National Bank’s holdings in Regeneron Pharmaceuticals were worth $6,530,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. CX Institutional grew its holdings in shares of Regeneron Pharmaceuticals by 10.7% during the third quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 30 shares during the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 20.0% in the third quarter. Valeo Financial Advisors LLC now owns 619 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 103 shares during the last quarter. HCR Wealth Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $202,000. Atlantic Union Bankshares Corp boosted its position in Regeneron Pharmaceuticals by 17.3% in the third quarter. Atlantic Union Bankshares Corp now owns 1,106 shares of the biopharmaceutical company’s stock valued at $910,000 after buying an additional 163 shares during the last quarter. Finally, PDS Planning Inc increased its holdings in Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. PDS Planning Inc now owns 338 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 26 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 1.1 %

Shares of REGN traded up $9.28 during midday trading on Monday, reaching $892.48. The company had a trading volume of 365,689 shares, compared to its average volume of 489,599. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm has a 50 day simple moving average of $946.89 and a 200-day simple moving average of $894.83. The stock has a market cap of $97.96 billion, a PE ratio of 25.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period last year, the business earned $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Barclays boosted their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Finally, Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.